中枢神经系统临床用PET显像剂的研究进展

doi:10.7538/tws.2019.youxian.044

摘要/Abstract

摘要：

中枢神经系统结构精密、功能复杂，目前对其认知不足。PET显像能从细胞分子水平动态观察受体、酶、基因表达、血流和物质代谢变化状况，不仅可以揭示中枢神经系统病理、生理、生化过程，还能对中枢神经系统疾病进行早期诊断及预后评估。PET靶向分子探针是大脑PET显像的关键。近年来，随着多模态分子成像、影像组学、人工智能等技术的发展，PET显像剂与其交叉学科的研究也成为热门。本文对中枢神经系统常用的PET显像剂与相关的研究进展进行综述，以期为这些探针在中枢神经系统临床疾病的诊治提供有益的参考。

关键词: 中枢神经系统, 正电子发射断层显像, 显像剂

Abstract:

Central nervous system is characterized by a sophisticated structure and complex functions. Nowadays, our knowledge about central nervous system is still insufficient. PET (positron emission computed tomography) imaging technique allows for dynamic observations for the changes of receptor, enzyme, gene expression, blood flow and metabolism process from the molecular level, and thus not only reveals physiological, pathological and biochemical processes of the central nervous system, but also provides an effective imaging means for the early diagnosis and prognosis evaluation of central nervous system diseases. PET targeting molecular probe is critical for PET imaging in the brain. In recent years, with the development of multi-modal molecular imaging, radiomics, artificial intelligence and other technologies, extensive studies on PET imaging agentradio-tracer and its interdisciplinary techniques are being performed. In this review, PET radio-tracers commonly used in the central nervous system were summarized so as to provide a useful guide for the diagnosis and treatment of diseases related to the central nervous system when these tracers are used.

Key words: central nervous system, PET, radio-tracers

邓虞娇;朱华;杨志;彭志平;贾建华. 中枢神经系统临床用PET显像剂的研究进展[J]. 同位素, 2020, 33(4): 250-262.

DENG Yujiao;ZHU Hua;YANG Zhi;PENG Zhiping;JIA Jianhua. Recent Progress of PET Radio-tracer for Clinical Use in Central Nervous System[J]. Journal of Isotopes, 2020, 33(4): 250-262.

参考文献

［1］Madunic I V, Madunic J, Breljak D, et al. Sodium-glucose cotransporters: new targets of cancer therapy?［J］. Arh Hig Rada Toksikol,2018,69(4):278-285.
［2］Li Y, Jiang J, Lu J, et al. Radiomics: a novel feature extraction method for brain neuron degeneration disease using ¹⁸F-FDG PET imaging and its implementation for Alzheimer’s disease and mild cognitive impairment［J］. Ther Adv Neurol Disord, 2019, 12: 1278060250.
［3］Muzic R J, Chandramouli V, Huang H M, et al. Human radiation dosimetry of 6-［¹⁸F］FDG predicted from preclinical studies［J］. Med Phys, 2014, 41(3): 31 910.
［4］Tahara N, Mukherjee J, de Haas H J, et al. 2-deoxy-2-［¹⁸F］fluoro-D-mannose positron emission tomography imaging in atherosclerosis［J］. Nat Med, 2014, 20(2): 215-219.
［5］BakFredslund K P, Lykke E P, Munk O L, et al. Metabolic liver function in humans measured by 2-¹⁸F-fluoro-2-deoxy-D-galactose PET/CT-reproducibility and clinical potential［J］. EJNMMI Res, 2017, 7(1): 71.
［6］Geisler S, Stegmayr C, Niemietz N, et al. Treatment-related uptake of O-(2-［¹⁸F］fluoroethyl)-L-tyrosine and L-［methyl-(3)H］-methionine after tumor resection in rat glioma models［J］. J Nucl Med, 2019. DOI: 10.2967/jnumed.119.225680.
［7］Mansoor N M, Thust S, Militano V, et al. PET imaging in glioma: techniques and current evidence［J］. Nucl Med Commun, 2018, 39(12): 1064-1080.
［8］Sommerauer M, Galldiks N, Barbe M T, et al. Cis-4-［¹⁸F］fluoro-D-proline detects neurodegeneration in patients with akinetic-rigid parkinsonism［J］. Nucl Med Commun, 2019, 40(4): 383-387.
［9］Verhoeven J, Hulpia F, Kersemans K, et al. New fluoroethyl phenylalanine analogues as potential LAT1-targeting PET tracers for glioblastoma［J］. Sci Rep, 2019, 9(1): 2878.
［10］Pena P F, Moreno J, Jimenez A F, et al. Diverse behavior in ¹⁸F-Fluorocholine PET/CT of brain tumors in patients with neurofibromatosis type 1［J］. Clin Nucl Med, 2019, 44(8): e472-e476.
［11］Estrade T L, Hansen H D, Erlandsson M, et al. Classics in Neuroimaging: the serotonergic 2A receptor system-from discovery to modern molecular imaging［J］. ACS Chem Neurosci,2018, 9(6): 1226-1229.
［12］Nikaki A, Papadopoulos V, Valotassiou V, et al. Evaluation of the performance of ¹⁸F-fluorothymidine positron emission tomography/computed tomography (18F-FLT-PET/CT) in metastatic brain lesions［J］. Diagnostics (Basel), 2019, 9(1) .DOI: 10.3390/diagnostics9010017.
［13］Liu Y, Yang Y, Sun M, et al. Highly specific noninvasive photoacoustic and positron emission tomography of brain plaque with functionalized croconium dye labeled by a radiotracer［J］. Chem Sci, 2017, 8(4): 2710-2716.
［14］Lewis D Y, Mair R, Wright A, et al. ［¹⁸F］fluoroethyltyrosine-induced cerenkov luminescence improves image-guided surgical resection of glioma［J］. Theranostics, 2018, 8(14): 3991-4002.
［15］Stenkrona P, Matheson G J, Cervenka S, et al. ［¹¹C］SCH23390 binding to the D1-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis［J］. EJNMMI Res, 2018, 8(1): 74.
［16］Kosaka J, Takahashi H, Ito H, et al. Decreased binding of ［¹¹C］NNC112 and ［¹¹C］SCH23390 in patients with chronic schizophrenia［J］. Life Sci, 2010, 86(21-22): 814-818.
［17］Hamilton J P, Sacchet M D, Hjornevik T, et al. Striatal dopamine deficits predict reductions in striatal functional connectivity in major depression: a concurrent ¹¹C-raclopride positron emission tomography and functional magnetic resonance imaging investigation［J］. Transl Psychiatry, 2018, 8(1): 264.
［18］Mitelman S A, Buchsbaum M S, Christian B T, et al. Dopamine receptor density and white mater integrity: ¹⁸F-fallypride positron emission tomography and diffusion tensor imaging study in healthy and schizophrenia subjects［J］. Brain Imaging Behav, 2018. DOI: 10.1007/s11682-018-0012-0.
［19］Nabulsi N B, Holden D, Zheng M Q, et al. Evaluation of ¹¹C-LSN3172176 as a novel PET tracer for imaging M1 muscarinic acetylcholine receptors in nonhuman primates［J］. J Nucl Med, 2019. DOI: 10.2967/jnumed.118.222034.
［20］Savitz J B, Drevets W C. Neuroreceptor imaging in depression［J］. Neurobiol Dis, 2013, 52: 49-65.
［21］Coughlin J, Du Y, Crawford J L, et al. The availability of the alpha7 nicotinic acetylcholine receptor in recent-onset psychosis: a study using ¹⁸F-ASEM PET［J］. J Nucl Med, 2018. DOI: 10.2967/jnumed. 118. 213686.
［22］Hillmer A T, Zheng M Q, Li S, et al. PET imaging evaluation of ［¹⁸F］DBT-10, a novel radioligand specific to alpha7 nicotinic acetylcholine receptors, in nonhuman primates［J］. Eur J Nucl Med Mol Imaging, 2016, 43(3): 537-547.
［23］Savitz J B, Drevets W C. Neuroreceptor imaging in depression［J］. Neurobiol Dis, 2013, 52: 49-65.
［24］Lerond J, Lothe A, Ryvlin P, et al. Effects of aripiprazole, risperidone, and olanzapine on 5-HT_1A receptors in patients with schizophrenia［J］. J Clin Psychopharmacol, 2013, 33(1): 84-89.
［25］Liow J S, Zoghbi S S, Hu S, et al. ¹⁸F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human bloodbrain barrier［J］. Neuroimage, 2016, 138: 134-140.
［26］Yatham L N, Liddle P F, Lam R W, et al. Effect of electroconvulsive therapy on brain 5-HT₂ receptors in major depression［J］. Br J Psychiatry, 2010, 196(6): 474-479.
［27］Meyer P T, Bhagwagar Z, Cowen P J, et al. Simplified quantification of 5-HT_2A receptors in the human brain with ［¹¹C］MDL 100,907 PET and non-invasive kinetic analyses［J］. Neuroimage, 2010, 50(3): 984-993.
［28］Landau A M, Alstrup A, Noer O, et al. Electroconvulsive stimulation differentially affects ［¹¹C］MDL100,907 binding to cortical and subcortical 5HT_2A receptors in porcine brain［J］. J Psychopharmacol, 2019: 1740142540.
［29］Lindberg A, Nag S, Schou M, et al. ［¹¹C］AZ10419096 -a full antagonist PET radioligand for imaging brain 5-HT_1Breceptors［J］. Nucl Med Biol, 2017, 54: 34-40.
［30］Tyacke R J, Nutt D J. Optimising PET approaches to measuring 5-HT release in human brain［J］. Synapse, 2015, 69(10): 505-511.
［31］Mc M B, Norgaard M, Svarer C, et al. Seasonality-resilient individuals downregulate their cerebral 5-HT transporter binding in winter-A longitudinal combined ¹¹C-DASB and ¹¹C-SB207145 PET study［J］. Eur Neuropsychopharmacol, 2018, 28(10): 1151-1160.
［32］Hazari P P, Pandey A, Chaturvedi S, et al. New trends and current status of positron-emission tomography and single-photon-emission computerized tomography radioligands for neuronal serotonin receptors and serotonin transporter［J］. Bioconjug Chem, 2017, 28(11): 2647-2672.
［33］Hammers A, Asselin M C, Hinz R, et al. Upregulation of opioid receptor binding following spontaneous epileptic seizures［J］. Brain, 2007, 130(Pt 4): 1009-1016.
［34］Joshi A, Fessler J A, Koeppe R A. Improving PET receptor binding estimates from Logan plots using principal component analysis［J］. J Cereb Blood Flow Metab, 2008, 28(4): 852-865.
［35］Li S, Zheng M Q, Naganawa M, et al. Novel kappa opioid receptor agonist as improved PET radiotracer: development and in vivo evaluation［J］. Mol Pharm, 2019, 16(4): 1523-1531.
［36］Yang L, Brooks A F, Makaravage K J, et al. Radiosynthesis of ［11C］LY2795050 for preclinical and clinical PET imaging using Cu(Ⅱ)-Mediated cyanation［J］. ACS Med Chem Lett, 2018, 9(12): 1274-1279.
［37］Pecina M, Zubieta J K. Expectancy modulation of opioid neurotransmission［J］. Int Rev Neurobiol, 2018, 138: 17-37.
［38］Theodore W H. Presurgical focus localization in epilepsy: PET and SPECT［J］. Semin Nucl Med, 2017, 47(1): 44-53.
［39］Urfer R, Moebius H J, Skoloudik D, et al. Phase II trial of the sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke［J］. Stroke, 2014, 45(11): 3304-3310.
［40］Jia H, Zhang Y, Huang Y. Imaging sigma receptors in the brain: new opportunities for diagnosis of Alzheimer’s disease and therapeutic development［J］. Neurosci Lett, 2019, 691: 3-10.
［41］Krishnan H S, Bernard-Gauthier V, Placzek M S, et al. Metal protein-attenuating compound for PET neuroimaging: synthesis and preclinical evaluation of ［¹¹C］PBT2［J］. Mol Pharm, 2018, 15(2): 695-702.
［42］Baskin A, Buchegger F, Seimbille Y, et al. PET molecular imaging of hypoxia in ischemic stroke: an update［J］. Curr Vasc Pharmacol, 2015, 13(2): 209-217.
［43］Smith R, Schain M, Nilsson C, et al. Increased basal ganglia binding of ¹⁸F-AV-1451 in patients with progressive supranuclear palsy［J］. Mov Disord, 2017, 32(1): 108-114.
［44］Ishiki A, Harada R, Okamura N, et al. Tau imaging with ［18F］THK5351 in progressive supranuclear palsy［J］. Eur J Neurol, 2017, 24(1): 130-136.
［45］George N, Gean E G, Nandi A, et al. Advances in CNS imaging agents: focus on PET and SPECT tracers in experimental and clinical use［J］. CNS Drugs, 2015, 29(4): 313-330.
［46］Funck T, Al-Kuwaiti M, Lepage C, et al. Assessing neuronal density in peri-infarct cortex with PET: effects of cortical topology and partial volume correction［J］. Hum Brain Mapp, 2017, 38(1): 326-338.
［47］Warnock G I, Aerts J, Bahri M A, et al. Evaluation of ¹⁸F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain［J］. J Nucl Med, 2014, 55(8): 1336-1341.
［48］Mercier J, Provins L, Valade A. Discovery and development of SV2A PET tracers: potential for imaging synaptic density and clinical applications［J］. Drug Discov Today Technol, 2017, 25: 45-52.
［49］Sakata M, Toyohara J, Ishibashi K, et al. Age and gender effects of ¹¹C-ITMM binding to metabotropic glutamate receptor type 1 in healthy human participants［J］. Neurobiol Aging, 2017, 55: 72-77.
［50］Sato H, Ito C, Hiraoka K, et al. Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers［J］. Psychopharmacology (Berl), 2015, 232(19): 3497-3505.
［51］Ernst D, Widera C, Weiberg D, et al. Beta-1-Adrenergic receptor antibodies in acute coronary syndrome: is less sometimes more?［J］. Front Cardiovasc Med, 2018, 5: 170.
［52］Cui L B, Liu L, Wang H N, et al. Disease definition for schizophrenia by functional connectivity using radiomics strategy［J］. Schizophr Bull, 2018, 44(5): 1053-1059.
［53］Skachokova Z, Martinisi A, Flach M, et al. Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice［J］. Acta Neuropathol Commun, 2019, 7(1): 72.
［54］Kikuchi T, Okamura T, Zhang M R, et al. PET probes for imaging brain acetylcholinesterase［J］. J Labelled Comp Radiopharm, 2013, 56(3-4): 172-179.
［55］Waterhouse R N, Chang R C, Atuehene N, et al. In vitro and in vivo binding of neuroactive steroids to the sigma-1 receptor as measured with the positron emission tomography radioligand［18F］FPS［J］. Synapse, 2007, 61(7): 540-546.
［56］Kitamura Y, Kozaka T, Miwa D, et al. Synthesis and evaluation of a new vesamicol analog o-［¹¹C］methyl-trans-decalinvesamicol as a PET ligand for the vesicular acetylcholine transporter［J］. Ann Nucl Med, 2016, 30(2): 122-129.
［57］Hong C M, Ryu H S, Ahn B C. Early perfusion and dopamine transporter imaging using ¹⁸F-FP-CIT PET/CT in patients with parkinsonism［J］. Am J Nucl Med Mol Imaging, 2018, 8(6): 360-372.
［58］Huang X, Xiao X, Gillies R J, et al. Design and automated production of ¹¹C-alpha-methyl-l-tryptophan (¹¹C-AMT)［J］. Nucl Med Biol, 2016, 43(5): 303-308.
［59］Hazari P P, Pandey A, Chaturvedi S, et al. New trends and current status of positron-emission tomography and single-photon-emission computerized tomography radioligands for neuronal serotonin receptors and serotonin transporter［J］. Bioconjug Chem, 2017, 28(11): 2647-2672.
［60］Lillethorup T P, Glud A N, Alstrup A, et al. Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs［J］. Exp Neurol, 2018, 303: 142-152.
［61］Nikolaus S, Muller H W, Hautzel H. Different patterns of dopaminergic and serotonergic dysfunction in manic, depressive and euthymic phases of bipolar disorder［J］. Nuklearmedizin, 2017, 56(5): 191-200.
［62］Zou J, Weng R H, Chen Z Y, et al. Position emission tomography/single-photon emission tomography neuroimaging for detection of premotor parkinson’s disease［J］. CNS Neurosci Ther, 2016, 22(3): 167-177.
［63］Baskin A, Buchegger F, Seimbille Y, et al. PET molecular imaging of hypoxia in ischemic stroke: an update［J］. Curr Vasc Pharmacol, 2015, 13(2): 209-217.

[1]	李忠勇;崔海平. 以Aβ为靶点的阿尔茨海默病PET显像剂的研究进展[J]. 同位素, 2020, 33(1): 27-37.
[2]	张锦明;杜进. 中国放射性药物制备的现状及展望[J]. 同位素, 2019, 32(3): 178-185.
[3]	高航;张华北. 中枢神经系统α7烟碱型乙酰神经胆碱受体显像剂研究进展[J]. 同位素, 2019, 32(3): 218-230.
[4]	刘炳楠;熊利平;姜申德;要少波. 16-表雌三醇的合成及放射性标记[J]. 同位素, 2018, 31(5): 283-290.
[5]	柳银黎;李忠勇. ¹⁸F-标记苯乙烯基氮杂环化合物的制备[J]. 同位素, 2018, 31(1): 33-41.
[6]	闫赋琴;周卫华;孙小萌;刘晓军. 腺苷A_2A受体显像剂¹¹C-KW6002的合成与初步生物学评价[J]. 同位素, 2017, 30(3): 204-208.
[7]	何玉林;张晓军;刘健;付华平;李云刚;张锦明. 三种碳-11标记的苯乙胺衍生物的合成与生物分布研究[J]. 同位素, 2017, 30(1): 9-15.
[8]	吴晓伟;张现忠. 孕激素受体靶向的放射性药物研究进展[J]. 同位素, 2017, 30(1): 63-70.
[9]	罗洪义;沈浪涛;梁积新;杨春慧;张文辉;秦少鹏;卫成军;刘海春;王建华;李洪玉. ^99mTc-帕米膦酸盐的制备及骨分布[J]. 同位素, 2016, 29(1): 6-11.
[10]	周明;张晓军;刘健;李云钢;张锦明. 国产FDG模块半自动合成¹⁸F-氟乙基胆碱[J]. 同位素, 2016, 29(1): 19-24.
[11]	尤强;陈跃;黄占文;王力. 诊断黑色素瘤的放射性药物研究进展[J]. 同位素, 2015, 28(4): 238-247.
[12]	张锦明;张晓军;黄德晖;王卉;刘健;田嘉禾. 多发性硬化症显像剂¹¹C-CIC的合成[J]. 同位素, 2015, 28(4): 259-264.
[13]	彭程;赵祚全;陈淑婷;马云川;张现忠;陆洁. ¹⁸F标记的新型鏻正阳离子PET心肌灌注显像剂的制备及生物性能评价[J]. 同位素, 2014, 27(4): 223-229.
[14]	唐彩华;胡孔珍;唐刚华. Alzheimer病PET显像剂研究进展[J]. 同位素, 2014, 27(1): 55-63.
[15]	甘满权;唐小兰;唐刚华;王红亮;胡孔珍. ¹¹C-乙酸盐自动化合成改进工艺及PET/CT显像[J]. 同位素, 2013, 26(2): 73-78.